aromasil has been researched along with Astrocytoma, Grade IV in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amarh, E; Assiri, AA; Dave, N; Overholser, BR; Pollok, KE; Shugg, T | 1 |
| Chen, G; Dang, YW; He, RQ; Luo, DZ; Xiong, DD; Xu, WQ | 1 |
2 other study(ies) available for aromasil and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma.
Topics: Androstadienes; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Glioblastoma; Humans; Letrozole | 2021 |
In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Topics: Androstadienes; Antineoplastic Agents; Brain Neoplasms; Computational Biology; Drug Discovery; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; MicroRNAs; Molecular Docking Simulation; Molecular Targeted Therapy; Sulfonamides; Transcriptome | 2019 |